Daiichi Sankyo to offset sales-related carbon footprint
This article was originally published in Scrip
In apparently the first such move by a Japanese pharmaceutical company in Japan, Daiichi Sankyois to purchase carbon credits to help offset exhaust emissions from its fleet of sales vehicles in Japan. The credits will be acquired through a route recognised by the Kyoto Protocol on global warming in a certified greenhouse gas reduction project in Ulsan, South Korea, to help offset sales-related company carbon dioxide emissions of 9,000 tonnes per annum. Daiichi Sankyo noted that it already employs fuel-efficient driving methods and low emission and hybrid vehicles in its sales efforts, which also make use of public transport.
You may also be interested in...
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.